Finally, we evaluated the selectivity of our top two compounds, SBI-2130 and SBI-4668, on MOLM-13 AML cells in which SHP2 was depleted using CRISPR–Cas9 KO. The gene discussed is PTPN11; the disease is acute myeloid leukemia.